CoChat

In Vitro and In Vivo Enhancement of Canine Pulmonary Alveolar Macrophage Cytotoxic Activity Against Canine Osteosarcoma Cells

Kurzman, Ilene D., Shi, Fushun, Vail, David M., MacEwen, E. Gregory · 1999 · Cancer Biotherapy and Radiopharmaceuticals
Cited by 46

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

The combination of chemotherapy with immunotherapy may offer an advantage over either therapy alone and provide a greater potential for total tumor eradication. Monocyte/macrophage-mediated tumor cell killing is a major mechanism of the host's defense against primary and/or metastatic neoplasia. We evaluated the tumoricidal activity against canine osteosarcoma cells of canine pulmonary alveolar macrophages (PAM) exposed in vitro to two recombinant canine (rc) cytokines (rcTNF alpha and rcIFN gamma). We also evaluated the in vivo tumoricidal activity of PAM from dogs treated with the macrophage activator, liposome-encapsulated muramyl tripeptide-phosphatidyl-ethanolamine (L-MTP-PE) alone or in combination with doxorubicin (DOX). This study demonstrated that rcTNF alpha and rcIFN gamma significantly enhance in vitro canine PAM cytotoxicity against canine osteosarcoma cells, and that PAM from dogs treated with DOX + L-MTP-PE have enhanced cytotoxic activity against osteosarcoma cells when compared to dogs treated with DOX or L-MTP-PE alone. These findings support the rationale for combining a chemotherapy agent with an immunotherapy agent for the treatment of metastatic disease, and suggest a role for TNF alpha and IFN gamma as agents for stimulating the antitumor activity of macrophages.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/cbr.1999.14.121

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 33

  1. Fidler IJ, 1985, Cancer Res, 45, 4714
  2. 10.1093/jnci/73.2.447 · doi:10.1093/jnci/73.2.447
  3. 10.1146/annurev.iy.02.040184.001435 · doi:10.1146/annurev.iy.02.040184.001435 · Paper page
  4. 10.1016/0952-7915(90)90031-B · DOI
  5. 10.1172/JCI110970 · doi:10.1172/jci110970
  6. Conkling PR, 1988, Cancer Res, 48, 5604
  7. Espinoza-Delgado I, 1990, J Immunol, 145, 1137, 10.4049/jimmunol.145.4.1137 · doi:10.4049/jimmunol.145.4.1137
  8. 10.1016/0165-2478(90)90174-O · DOI
  9. Demetri GD, 1992, Seminars in Oncol, 19, 362
  10. Van de Loosdrecht A, 1993, Cancer Res, 53, 4399
  11. Martin JH, 1994, Immunology, 81, 592
  12. 10.1016/S0171-2985(89)80049-X · DOI
  13. Zucker K, 1994, Coli. Lymph Cytokine Res, 13, 191
  14. Fogler WE, 1984, NY, 499
  15. 10.1073/pnas.78.3.1680 · DOI · Paper page
  16. Fidler IJ, 1982, J Biol Resp Modif, 1, 43
  17. 10.1007/BF00046339 · DOI · Paper page
  18. 10.3727/095535491820873740 · DOI
  19. 10.1007/BF01878149 · DOI
  20. 10.1016/S0022-5347(17)43178-8 · doi:10.1016/s0022-5347(17)43178-8
  21. 10.1093/jnci/81.24.1904 · doi:10.1093/jnci/81.24.1904
  22. Utsugi T, 1990, Cancer Res, 50, 2636
  23. Jia SF, 1991, Proc Am Assoc Cancer Res, 32, 227
  24. 10.1093/jnci/55.6.1265 · DOI · Paper page
  25. Rosenthal RC, 1989, Philadelphia, 63
  26. Stoychkov JN, 1979, Cancer Res, 39, 3014
  27. Ehrke MJ, 1984, Cancer Res, 44, 2497
  28. Arinaga S, 1986, Cancer Res, 46, 4213
  29. 1988, Cancer Res, 48, 5256
  30. Ehrke MJ, 1989, Semin Oncol, 16, 230
  31. 1993, Cancer Res, 53, 3986
  32. Vail DM, 1995, Am J Vet Res, 56, 282, 10.2460/ajvr.1995.56.03.282 · doi:10.2460/ajvr.1995.56.03.282
  33. 10.1089/cbr.1993.8.137 · doi:10.1089/cbr.1993.8.137

Cited by

Metadata

Authors
Kurzman, I. D., Shi, F., Vail, D. M., & MacEwen, E. G.
Venue
Cancer Biotherapy and Radiopharmaceuticals
Published
1999-04
Volume
14
Issue
2
Pages
121-128
ISSN
  • 1084-9785 (ISSN-L)
  • 1557-8852
OpenAlex
W2043296164
Cited by
46
References
1
FWCI
0.11
Type
journal article
Language
en
Open access
closed
Licence
www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.